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Abstract
Background To evaluate the effectiveness of endolaser pho-
tocoagulation by a two-port pars plana nonvitrectomy ap-
proach for treating Coats’ disease with shallow exudative ret-
inal detachment.
Methods This study included 24 patients (23 boys with an age
range of 2–17 years, and one girl, age 6 years) with stage 3
Coats’ disease (25 eyes) from December 2012 and May
2014 at a single center. All of the 25 eyes were complicated
with serous or total retinal detachment and received none-
vitrectomized endolaser: two (23- or 25-gauge) incisions were
routinely made 3 mm posterior to the corneal limbus and a
laser was applied directly on the abnormal blood vessels. Ad-
ditional treatments included subretinal fluid drainage (five
eyes), intravitreal triamcinolone injection (seven eyes), and
intravitreal anti-vascular endothelial growth factor (VEGF)
injection (17 eyes). Best-corrected visual acuity, intraocular
pressure, and fundus and abnormal vascular changes were
recorded to determine therapeutic effects.
Results Twenty-four out of the 25 treated eyes (96 %) had
retina reattached. The number of treatment sessions differed
case by case (1–5 sessions, average 1.96) and the time to full
treatment of retinal reattachment was 4 months in average.
One patient (4 %) presented with retinal redetachment. Five
(20 %) eyes received further laser treatment with indirect oph-
thalmoscope and four eyes (16 %) presented with total retinal
detachment at their first visits received consecutive treatments.
At the end of the follow-up period (mean, 10.08 months),
telangiectasias of 24 (96 %) eyes were resolved and no severe
complications occurred.
Conclusions Endolaser photocoagulation by a two-port pars
plana nonvitrectomy approach is an effective treatment for
advanced Coats’ disease with serous retinal detachment. The
long-term safety of the approach needs further investigation.
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Introduction
In 1908, George Coats [1] described an ocular entity charac-
terized by unilateral retinal vascular abnormalities and retinal
exudation usually in boys. Coats’ disease is associated with
excessive production of yellowish intraretinal and subretinal
exudates [2] and can cause retinal detachment and severe vi-
sual loss [3]. Its common signs are decreased visual acuity,
strabismus, and leukocoria [4].
Shields et al. [5] proposed the most recent classification
with the following stages: stage 1, telangiectasia only; stage
2, telangiectasia and exudation (2A, extrafoveal exudation;
2B, foveal exudation); stage 3, exudative retinal detachment
(3A, subtotal; 3B, total); stage 4, total detachment and second-
ary glaucoma; and stage 5, advanced end-stage disease.
Multiple modalities have been employed to treat Coats’
disease, including diathermy, laser photocoagulation, cryo-
therapy, subretinal fluid drainage, scleral buckling surgery,
pars plana vitrectomy, and intravitreal anti-vascular endothe-
lial growth factor (VEGF) therapy [6–8]. Treatment is aimed
at destroying abnormal vasculature and aneurysmal dilations.
Nucc et al. first reported selective photocoagulation and
young Coats’ patients responded quickly to laser treatment
[9]. In advanced cases with serous retinal detachment, laser
photocoagulation may not be able to reach the vessels, leading
to persistence of subretinal fluid and necessitating multiple
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courses of treatment [10]. Eyes with advanced Coats’ disease
and total retinal detachment may require pars plana vitrectomy
with internal or external drainage of subretinal fluid, laser
photocoagulation, and silicone oil tamponade.
The purpose of this retrospective study was to assess the
effectiveness of endolaser photocoagulation by a two-port
pars plana nonvitrectomy approach for treating Coats’ disease
with moderate-to-severe serous retinal detachment.
Materials and methods
Medical records of 24 patients (25 eyes) with stage 3 Coats’
disease diagnosed from December 2012 to May 2014 at a
single center were reviewed. All of them presented with se-
rous or total retinal detachment that could not be reached by
regular laser photocoagulation and thus undertook minimally
invasive operations of endolaser photocoagulation. Some
cases were treated combined with drainage of the subretinal
fluid, intravitreal triamcinolone injection or anti-VEGF injec-
tion. Patient consent was obtained.
Clinical information, including birth history, age, gender,
family history, medical history, and systemic and other ocular
anomalies, was assessed. All patients routinely underwent in-
direct ophthalmoscopy. Wide-angle retina photography
(RetCam; Clarity Medical Systems, Pleasanton, CA, USA)
was performed in patients younger than 5 years and fundus
photography (Optos 200Tx; Optos, Dunfermline, Scotland,
UK) was performed in older cooperative patients.
All surgical procedures were performed under general an-
esthesia by the same experienced surgeon. Two 23- or 25-
gauge incisions were made 3 mm posterior to the corneal
limbus and the retina was examined. The surgical procedure
commenced with the examine of the retinal vessels, followed
by laser directly on the entire network of telangiectatic vessels
and the injection of viscoelastics afterwards to minimize vit-
reous traction at the side ports (Figs. 1 and 2). Telangiectasias
were ablated with a 532-nm green endolaser; the power was
adjusted according to the retinal reaction to laser spots. A
noncontact wide-angle viewing system was used to visualize
the fundus. Endolaser therapy was discontinued when whit-
ening of telangiectatic vessels was observed.
Additional treatments such as intravitreal triamcinolone or
anti-VEGF injection and further surgery were performed
based on findings of fundus fluorescein angiography, condi-
tions during endolaser photocoagulation, and postoperative
outcomes. Therapeutic effects were determined according to
the patients’ visual acuity, intraocular pressure, fundus and
abnormal vascular changes.
All the patients were born at full term or late preterm, with a
birth weight above 2,500 g. None had a related family history.
The study population comprised 23 boys (95.83 %) and one
girl (4.17 %); patient age ranged from 2 to 17 years (mean,
6.21 years). Patients were divided into three groups according
to the severity of the disease and previous treatment regimens
and the data are presented in Table 1.
Group A (nine eyes) received laser photocoagulation
and/or cryopexy before, however, the treatment above
could not stop the vascular abnormalities, thus these pa-
tients received the endolaser. Group B (11 eyes) was ini-
tiated with endolaser treatment regimen due to the pres-
ence of serous retinal detachment. Patients in group C
(five eyes) were in stage 3B, received external drainage
of subretinal fluid plus non-vitrectomized vitrectomy. Ad-
ditionally, triamcinolone and anti-VEGF were injected ac-
cording to the condition of abnormal vessels. Visual acu-
ity, intraocular pressure, eye position, slit-lamp micro-
scope, indirect ophthalmoscope, and color fundus imaging
were followed up (average, 10.08 months, range, 1–
20 months).
Fig. 1 Illustration of the surgical
procedure of a 4-year-old boy
with stage 3A Coats’ disease
(OS). Top left Two 23-gauge in-
cisions made 3 mm posterior to
the corneal limbus. Top right Two
25-gauge incisions made 3 mm
posterior to the corneal limbus.
Bottom left Endolaser ablation of
telangiectasias. Bottom center
Endolaser in the noncontact wide-
field viewing system. Bottom
right Anti-vascular endothelial
growth factor (VEGF) injection
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Results
At the end of the follow-up period, 24 (96 %) eyes had the
retina reattached, telangiectasias were resolved, and no severe
complications occurred. In groups A and B, the exudation
involved 3.25 quadrants (range, 2–4). Regular laser therapy
under indirect ophthalmoscopy was barely effective on the
abnormal vessels with exudative retinal detachment and se-
rous retinal detachment and endolaser could shorten the period
of recovery. The average sessions to full treatment of active
telangiectasia and retinal reattachment was 4 months (range,
1–10 months); only one (4.17 %) eye progressed to retinal
detachment due to lack of follow-up. Each eye received 1–5
sessions of treatments (average, 1.96 times) (Table 2). In-
creased intraocular pressure in one (4.17 %) eye after surgery
was controlled with eye drops.
Seven and 17 eyes required subsequent intravitreal triam-
cinolone and anti-VEGF injections, respectively. These injec-
tions were not associated with endophthalmitis or
Fig. 2 Drainage of subretinal
fluid of a 2-year-old boy with
stage 3B Coats’ disease (OS)
Table 1 Patient information




A 1 OS M 3 18
2 OD M 2 16
3 OD M 8 14
4 OD M 17 14
5 OU M 3 15
6 OS M 11 7
7 OS M 5 6
8 OD M 5 4
9 OD M 3 1
B 1 OS M 13 18
2 OS M 9 17
3 OD M 5 16
4 OS M 9 16
5 OD M 2 14
6 OS M 3 12
7 OD M 6 4
8 OS M 5 4
9 OD M 9 3
10 OD M 6 3
11 OD M 9 2
C 1 OS M 4 20
2 OU M 3 15
3 OS M 2 11
4 OD M 4 4
5 OS F 6 3
Table 2 Patient treatments
Group Patient Range of exudation (quadrant) Treatments (sessions)
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systemically observed complications. Among the 17 patients
who would cooperate with visual examination, five (29.41 %)
had improved visual acuity at the end of the treatment session.
Because of recurrence of miliary aneurysms, two (22.22%)
eyes in group A and two (18.18 %) eyes in group B had
consecutive regular laser ablation at 1 to 6 months (average,
2.25 months) afterward the endolaser treatment. Most exuda-
tion was absorbed with a flat retina until the last follow-up
(Fig. 3). The five patients in group C who presented with total
retinal detachment, undertook drainage of the subretinal fluid
combined with anti-VEGF injection, received two-port
endolaser ablation and regular laser or other treatments after-
wards (Fig. 4). Among them, one eye developed fibrosis in the
peripheral retina 4 months after endolaser treatment, so three-
port pars plana vitrectomy was performed and the retina final-
ly reattached after three sessions without obvious telangiecta-
sia and the exudation absorption. No enucleation was ulti-
mately necessary.
Discussion
The treatment of Coats’ disease depends mainly on its sever-
ity. The overall aims of treatment in mild disease are ablation
of abnormal retinal vasculature, preservation of vision, and
prevention of retinal detachment [11]. In advanced cases, the
aim is to save the eyeball. In our study, we performed the two-
port endolaser with the help with noncontact wide-angle view-
ing system and fluorescein fundus angiography to guarantee
the treatment.
Laser ablation remains the mainstay of treatment. In the
present study, vision improved in 29.41 % of the eyes.
Schefler et al. [12] showed that 50 % of the patients with
Coats’ disease can retain useful vision with aggressive repet-
itive diode laser therapy even if the disease is advanced at
presentation. The difference in outcomes can be explained
by the disease severity: the present study included patients
with stage 3 Coats’ disease with local or total exudative retinal
Fig. 3 Fundus views of a 2-year-old boy with stage 3A Coats’ disease (OD). Left Preoperative view. Center Postoperative view during anti-vascular
endothelial growth factor (VEGF) injection. Right Postoperative view at 13 months
Fig. 4 Fundus views of a 3-year-
old boy with stage 3B Coats’ dis-
ease (OD). Top left Preoperative
view. Top right View at 1 week
after SRF drainage. Bottom left
View at 2 months after endolaser.
Bottom right View at 2 months
after supplementary laser
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detachment. According to our experience, this stage is consid-
ered less responsive to laser therapy under indirect ophthal-
moscopy and the prognosis is worse than those of stages 1 and
2. Further, exudation in the macular area took longer to absorb
than peripheral retinal exudation and vision of eyes with mac-
ular exudation was not satisfactory in the study.
In this study, we provided a new choice of treating stage 3
Coats’ disease. Yoshizumi et al. [13] and Kranias and Krebs
[14] reported successful management of advanced Coats’ dis-
ease with pars plana vitrectomy and air–fluid exchange.
Susskind et al. used PPV, including a modified technique of
exocryotherapy applied after fluid–air exchange to reduce as-
sociated side effects and improve the rehabilitation process of
advanced Coats’ disease patients [15]. In the present study,
stage 3B Coats’ disease was treated by subretinal fluid drain-
age, endolaser photocoagulation, and anti-VEGF injection.
Cryotherapy and silicone oil tamponade was not performed
to avoid the damage to the eyeball and the need for secondary
surgeries. In two cases, endolaser photocoagulation was per-
formed immediately after subretinal fluid drainage to mini-
mize treatment sessions. The other patients underwent the
procedure 1 week after drainage.
To our knowledge, this is the first time the two-port
pars plana nonvitrectomy approach for treating Coats’ dis-
ease has been reported in the literature. The proposed
technique has several advantages. First, it resolves the
problem associated with laser ablation in eyes with serous
retinal detachment where telangiectasias cannot be
reached by regular laser ablation. We applied a laser di-
rectly to telangiectasia within the retina without targeting
the RPE to create thermal injury. Second, it is non-
vitrectomized and is much less invasive than three-port
pars plana vitrectomy. Third, when combined with periph-
eral retinal examination, the procedure could be more
thorough and efficient, so the number of treatment ses-
sions could be reduced. To minimize vitreous traction at
the side ports, injection of viscoelastics was performed
afterwards and turned out to be an effective measure.
Shields et al. [5] reported that carefully selected treatment
can anatomically stabilize eyes or improve Coats’ disease
in 76 % of the cases. The present treatment yielded better
results: 96 % of the eyes showed retinal reattachment and
no active telangiectasias.
Bevacizumab and ranibizumab should be used cautiously
in patients with Coats’ disease to avoid vitreoretinal fibrosis
and tractional retinal detachment [16]. ATaiwanese study [17]
showed that cryotherapy combined with intravitreal
bevacizumab injection in severe cases of exudative retinal
detachment carries the risk of vitreoretinal fibrosis and trac-
tional retinal detachment. In the present study, only one eye
developed vitreoretinal fibrosis 4 months after anti-VEGF in-
jection, which was in group C and the fibrosis might be con-
nected with the serious disease or the treatments received.
Extended serial follow-up is important to evaluate the safety
of this treatment and usage of anti-VEGF injection. Supple-
mental treatment is required for new or recurrent lesions.
Conclusions
Endolaser photocoagulation by two-port pars plana
nonvitrectomy is a safe and effective approach in treating
advanced Coats’ disease with serous retinal detachment. Fur-
ther investigation of this promising technique is warranted.
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